Haramandeep Singh, MD
Psychiatry · San Ramon
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 8
Offices
8 locations · Haramandeep Singh MD Inc · Ridgecrest Regional Hospital · Integrated Sleep Care PC · Manakai O Malama Integrative · Maryland Medical Specialists Inc · Alpha Diagnostics Management Inc. · Bay Area Hospital District · Oregon Sleep and Pulmonary LLC
Hospitals listed: Bay Area Hospital · Ridgecrest Regional Hospital · Trego County Lemke Memorial Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singh’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A101826 · Current
Licensed to practise in California · since 2007 · expires 2027-07-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
2 licences
- Illinois 036107869Licensed Physician And Surgeon · since 2002 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
- Washington MD.MD.60909889Physician And Surgeon License · since 2019 · expires 2027-07-22ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Bay Area HospitalCoos Bay, ORAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
- Ridgecrest Regional HospitalRidgecrest, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Trego County Lemke Memorial HospitalWakeeney, KSCritical Access Hospital · Government - Local · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for Bay Area Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 1 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.78 (0.8 to 2.75) · 578 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.15 (0.8 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.57 (113.14 to 224.01) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.8 · 126 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.6 · 373 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 169 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,691 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.08 to 0.51) · 4,318 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.35 (0.14 to 0.55) · 4,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.31 (1.17 to 5.45) · 869 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.21 (0.64 to 3.79) · 321 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.92 (0.34 to 3.49) · 841 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.17 (0.74 to 15.61) · 324 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.15 (0.62 to 7.69) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.23 (0.77 to 3.69) · 217 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.18 (0.41 to 1.94) · 3,188 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.7 · 96 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.914 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.753 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.945 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.545 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 214 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -7.4 · 204 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.4 · 413 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.8 · 340 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 345 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.9 to 7.9) · 220 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (7.3 to 13) · 220 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 9.2 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12 (9 to 16) · 214 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.5) · 347 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,158 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Ridgecrest Regional Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.2 (9 to 16.5) · 384 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 67 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Trego County Lemke Memorial Hospital
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 1 better, 2 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 53 cases | None | Jul 2024 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.4) · 124 cases | No different | Jan 2022 – Dec 2024 |
Original Medicare doctor bills
$717,510
Medicare paid this office $717,510 for 3,648 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Sleep study including heart rate, breathing, and sleep time | 3,012 | $400,447 | $127 |
| New patient visit (30+ min) | 1,916 | $117,285 | $61 |
| Short return visit (20+ min) | 1,661 | $109,792 | $56 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 58 | $30,673 | $495 |
| Return visit (30+ min) | 188 | $21,258 | $95 |
See all 10 services
| Sleep study including heart rate, breathing, and sleep time | 3,012 | $400,447 | $127 |
| New patient visit (30+ min) | 1,916 | $117,285 | $61 |
| Short return visit (20+ min) | 1,661 | $109,792 | $56 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 58 | $30,673 | $495 |
| Return visit (30+ min) | 188 | $21,258 | $95 |
| New patient visit (45+ min) | 102 | $11,627 | $114 |
| Sleep study in sleep lab (6 years or older) | 21 | $9,924 | $473 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 76 | $7,594 | $95 |
| Sleep study in sleep lab (6 years or older) | 78 | $7,224 | $93 |
| Sleep study including heart rate, breathing, airflow, and effort | 12 | $411 | $34 |
Who their Medicare patients are
3,648 Original Medicare patients in 2024. Average age 71 · Under 65 7% · 85 and older 3% · Women 53% · Also on Medicaid 7% · Health risk score 0.95. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: High blood pressure 70% · Coronary heart disease 27% · Diabetes 26% · Depression 25% · Chronic kidney disease 19% · Atrial fibrillation 17% · Cancer 14% · Heart failure 11% · COPD 11% · Stroke 7% · Dementia 3%.
The office billed $3,504,725, Medicare allowed $972,128 and paid $717,510; for 7,643 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 3,648 | 7,643 | 71 | 0.95 | $3,504,725 | $717,510 |
| 2023 | 2,214 | 5,245 | 71 | 0.89 | $2,617,450 | $596,101 |
| 2022 | 1,309 | 4,329 | 71 | 0.85 | $2,295,288 | $528,836 |
| 2021 | 1,247 | 6,069 | 71 | 0.88 | $2,747,841 | $567,401 |
| 2020 | 918 | 5,355 | 70 | 1.04 | $1,963,639 | $442,792 |
| 2019 | 685 | 5,351 | 71 | 1.10 | $1,512,517 | $292,200 |
| 2018 | 614 | 3,748 | 69 | 1.12 | $1,187,407 | $244,909 |
| 2017 | 605 | 4,999 | 69 | 1.17 | $1,547,022 | $290,566 |
| 2016 | 487 | 7,056 | 70 | 1.15 | $1,595,298 | $309,480 |
| 2015 | 459 | 1,627 | 70 | 1.15 | $1,356,383 | $247,036 |
| 2014 | 410 | 1,454 | 70 | 1.01 | $1,182,674 | $229,136 |
| 2013 | 404 | 1,566 | 70 | 1.11 | $1,212,607 | $253,165 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Sleep study including heart rate, breathing, and sleep time | 1,804 | $290,727 | $149 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 100 | $63,357 | $615 |
| New patient visit (30+ min) | 882 | $57,441 | $65 |
| Short return visit (20+ min) | 787 | $50,735 | $58 |
| Sleep study in sleep lab (6 years or older) | 73 | $44,417 | $608 |
| New patient visit (45+ min) | 424 | $42,979 | $101 |
| Return visit (30+ min) | 358 | $32,499 | $83 |
| Sleep study in sleep lab (6 years or older) | 59 | $5,648 | $94 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 34 | $3,327 | $95 |
| Sleep study including heart rate, breathing, airflow, and effort | 15 | $1,075 | $67 |
2022: 14 services
| Sleep study including heart rate, breathing, and sleep time | 825 | $250,277 | $160 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 97 | $67,229 | $640 |
| New patient visit (45+ min) | 605 | $62,877 | $104 |
| Return visit (30+ min) | 567 | $53,293 | $84 |
| Sleep study in sleep lab (6 years or older) | 76 | $42,933 | $565 |
| Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | 174 | $11,175 | $40 |
| New patient visit (30+ min) | 145 | $9,392 | $65 |
| Short return visit (20+ min) | 143 | $9,128 | $60 |
| Sleep study in sleep lab (6 years or older) | 50 | $4,923 | $98 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 26 | $4,101 | $93 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 22 | $2,498 | $104 |
| Long return visit (40+ min) | 14 | $2,281 | $143 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 26 | $2,067 | $48 |
| Sleep study including heart rate, breathing, airflow, and effort | 14 | $1,072 | $77 |
2021: 13 services
| Sleep study including heart rate, breathing, and sleep time | 425 | $133,963 | $171 |
| Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | 282 | $90,015 | $47 |
| Return visit (30+ min) | 558 | $67,034 | $88 |
| New patient visit (45+ min) | 568 | $63,777 | $112 |
| Sleep study including heart rate, breathing, airflow, and effort | 311 | $59,793 | $100 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 64 | $47,877 | $665 |
| Sleep study in sleep lab (6 years or older) | 65 | $37,466 | $576 |
| Short return visit (20+ min) | 356 | $28,656 | $56 |
| New patient visit (60+ min) | 91 | $14,112 | $155 |
| New patient visit (30+ min) | 122 | $7,048 | $58 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 36 | $3,915 | $98 |
| Sleep study in sleep lab (6 years or older) | 21 | $1,953 | $93 |
| Long return visit (40+ min) | 14 | $1,880 | $134 |
2020: 16 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 276 | $103,843 | $65 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 87 | $60,699 | $660 |
| Return visit (30+ min) | 249 | $43,323 | $98 |
| Short return visit (20+ min) | 382 | $36,702 | $65 |
| New patient visit (45+ min) | 209 | $31,215 | $149 |
| Sleep study including heart rate, breathing, airflow, and effort | 148 | $28,619 | $114 |
| Sleep study including heart rate, breathing, and sleep time | 126 | $28,210 | $174 |
| Sleep study in sleep lab (6 years or older) | 47 | $24,183 | $515 |
| Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | 193 | $19,067 | $54 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 29 | $16,320 | $302 |
| New patient visit (60+ min) | 81 | $14,694 | $181 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 101 | $11,042 | $100 |
| Sleep study in sleep lab (6 years or older) | 68 | $6,567 | $97 |
| New patient visit (30+ min) | 68 | $6,212 | $91 |
| Test for allergy using allergenic extract | 15 | $4,915 | $4 |
| Sleep study including heart rate, breathing, airflow, and effort | 24 | $640 | $27 |
2019: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 91 | $71,341 | $667 |
| Sleep study in sleep lab (6 years or older) | 87 | $56,499 | $635 |
| Return visit (30+ min) | 224 | $43,352 | $98 |
| Short return visit (20+ min) | 337 | $33,106 | $65 |
| Test for allergy using allergenic extract | 45 | $14,733 | $4 |
| New patient visit (60+ min) | 79 | $13,784 | $174 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 31 | $11,853 | $289 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 85 | $9,372 | $100 |
| Sleep study in sleep lab (6 years or older) | 92 | $8,668 | $93 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 90 | $7,497 | $67 |
| New patient visit (45+ min) | 43 | $6,099 | $142 |
| Sleep study including heart rate, breathing, airflow, and effort | 40 | $4,643 | $116 |
| New patient visit (30+ min) | 25 | $2,247 | $90 |
| Sleep study including heart rate, breathing, airflow, and effort | 16 | $647 | $40 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 12 | $587 | $49 |
2018: 12 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 79 | $64,421 | $671 |
| Return visit (30+ min) | 234 | $40,039 | $95 |
| Sleep study in sleep lab (6 years or older) | 47 | $31,398 | $641 |
| Short return visit (20+ min) | 260 | $23,809 | $63 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 46 | $21,383 | $285 |
| New patient visit (60+ min) | 72 | $12,823 | $178 |
| Test for allergy using allergenic extract | 29 | $12,041 | $5 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 99 | $11,120 | $98 |
| New patient visit (45+ min) | 48 | $7,142 | $149 |
| Sleep study including heart rate, breathing, airflow, and effort | 45 | $6,331 | $127 |
| Sleep study in sleep lab (6 years or older) | 59 | $5,528 | $92 |
| New patient visit (30+ min) | 17 | $1,437 | $85 |
2017: 13 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 116 | $87,548 | $649 |
| Sleep study in sleep lab (6 years or older) | 76 | $46,780 | $616 |
| Return visit (30+ min) | 191 | $30,087 | $91 |
| Short return visit (20+ min) | 253 | $23,738 | $61 |
| Test for allergy using allergenic extract | 44 | $20,470 | $6 |
| Therapy procedure using a positive pressure ventilator | 217 | $18,132 | $51 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 33 | $16,745 | $275 |
| New patient visit (60+ min) | 71 | $11,941 | $168 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 95 | $10,758 | $101 |
| Sleep study in sleep lab (6 years or older) | 73 | $6,991 | $96 |
| New patient visit (45+ min) | 48 | $6,856 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,125 | $177 |
| Sleep study including heart rate, breathing, airflow, and effort | 11 | $1,647 | $137 |
2016: 12 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 127 | $93,527 | $632 |
| Sleep study in sleep lab (6 years or older) | 103 | $62,064 | $603 |
| Test for allergy using allergenic extract | 75 | $34,740 | $6 |
| Short return visit (20+ min) | 251 | $25,660 | $60 |
| Return visit (30+ min) | 162 | $25,619 | $92 |
| Therapy procedure using a positive pressure ventilator | 226 | $20,531 | $52 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 25 | $11,752 | $273 |
| New patient visit (60+ min) | 63 | $10,649 | $169 |
| New patient visit (45+ min) | 56 | $7,380 | $132 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 40 | $4,835 | $103 |
| Sleep study in sleep lab (6 years or older) | 28 | $2,698 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,684 | $168 |
2015: 10 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 130 | $90,298 | $627 |
| Sleep study in sleep lab (6 years or older) | 101 | $61,987 | $602 |
| Short return visit (20+ min) | 214 | $21,309 | $60 |
| Therapy procedure using a positive pressure ventilator | 188 | $19,004 | $55 |
| Return visit (30+ min) | 141 | $18,691 | $85 |
| New patient visit (60+ min) | 74 | $12,690 | $171 |
| New patient visit (45+ min) | 41 | $5,299 | $129 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 31 | $3,320 | $104 |
| Sleep study in sleep lab (6 years or older) | 28 | $2,798 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,444 | $175 |
2014: 10 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 126 | $84,825 | $619 |
| Sleep study in sleep lab (6 years or older) | 76 | $46,774 | $592 |
| Return visit (30+ min) | 161 | $24,304 | $85 |
| Therapy procedure using a positive pressure ventilator | 182 | $20,953 | $53 |
| Short return visit (20+ min) | 184 | $19,897 | $59 |
| New patient visit (60+ min) | 79 | $13,288 | $168 |
| New patient visit (45+ min) | 31 | $4,013 | $129 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 29 | $3,017 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,607 | $174 |
| Sleep study in sleep lab (6 years or older) | 23 | $2,163 | $94 |
2013: 11 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 121 | $84,321 | $649 |
| Sleep study in sleep lab (6 years or older) | 88 | $56,720 | $617 |
| Return visit (30+ min) | 204 | $44,418 | $85 |
| Therapy procedure using a positive pressure ventilator | 174 | $24,603 | $56 |
| New patient visit (60+ min) | 83 | $13,768 | $166 |
| Short return visit (20+ min) | 95 | $7,816 | $62 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 43 | $4,321 | $100 |
| New patient visit (45+ min) | 25 | $3,406 | $136 |
| Sleep study in sleep lab (6 years or older) | 30 | $2,903 | $97 |
| Long return visit (40+ min) | 21 | $2,609 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,510 | $157 |
Medicaid work
$100,050 in 2024
Medicaid paid $100,050 for 1,824 billed services this clinician did in 2024, up to 35 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap | 296 | $25,742 |
| Cont airway pressure device | 351 | $23,379 |
| Tubing with integrated heating element for use with positive airway pressure device | 299 | $14,676 |
| Pillow for use on nasal cannula type interface, replacement only, pair | 170 | $13,405 |
| Cushion for use on nasal mask interface, replacement only, each | 70 | $9,424 |
| Filter, disposable, used with positive airway pressure device | 365 | $4,698 |
| Headgear used with positive airway pressure device | 156 | $4,637 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 17 | $2,477 |
| Water chamber for humidifier, used with positive airway pressure device, replacement, each | 100 | $1,611 |
| 2024 | 1,824 | 9 | 35 | $100,050 |
| 2023 | 2,035 | 9 | 43 | $100,418 |
| 2022 | 485 | 8 | 46 | $23,339 |
| 2021 | 25 | 1 | 12 | $4,540 |
| 2020 | 158 | 2 | 33 | $11,425 |
| 2018 | 12 | 1 | 12 | $1,659 |
See the largest Medicaid services in earlier years
2023
| Cont airway pressure device | 437 | $28,584 |
| Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap | 315 | $24,813 |
| Tubing with integrated heating element for use with positive airway pressure device | 297 | $12,517 |
| Cushion for use on nasal mask interface, replacement only, each | 89 | $11,587 |
| Pillow for use on nasal cannula type interface, replacement only, pair | 142 | $10,314 |
| Headgear used with positive airway pressure device | 198 | $5,431 |
| Filter, disposable, used with positive airway pressure device | 392 | $4,265 |
| Water chamber for humidifier, used with positive airway pressure device, replacement, each | 125 | $1,704 |
| Pos airway pressure tubing | 40 | $1,204 |
2022
| Cont airway pressure device | 215 | $13,144 |
| Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap | 55 | $3,708 |
| Tubing with integrated heating element for use with positive airway pressure device | 48 | $1,940 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 12 | $1,723 |
| Filter, disposable, used with positive airway pressure device | 97 | $890 |
| Pillow for use on nasal cannula type interface, replacement only, pair | 13 | $783 |
| Headgear used with positive airway pressure device | 30 | $774 |
| Pos airway pressure tubing | 15 | $377 |
2021
| Return visit (30+ min) | 25 | $4,540 |
2020
| SBSQ NURSING FACILITY CARE HIGH MDM 45 MINUTES | 144 | $10,241 |
| Short return visit (20+ min) | 14 | $1,184 |
2018
| Return visit (30+ min) | 12 | $1,659 |
Drugs they prescribed that Part D paid
$1,903,886
Pharmacies billed $1,903,886 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 147) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
28 generic and 119 brand-name prescriptions · $1,903,886 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xywav | 64 | $1,019,610 | $15,931 |
| Wakix | 28 | $424,875 | $15,174 |
| Sodium Oxybate | 12 | $181,742 | $15,145 |
Year by year
| 2024 | 147 | 21 | 0% (0) | 81% | $1,903,886 |
| 2023 | 241 | 28 | 0% (0) | 53% | $1,762,593 |
| 2022 | 415 | 49 | 0% (0) | 42% | $1,715,817 |
| 2021 | 573 | 71 | 0% (0) | 40% | $1,871,271 |
| 2020 | 607 | 87 | 0% (0) | 40% | $1,896,019 |
| 2019 | 664 | 97 | 0% (0) | 27% | $995,539 |
| 2018 | 554 | 80 | 0% (0) | 31% | $824,681 |
| 2017 | 402 | 84 | 0% (0) | 21% | $291,863 |
| 2016 | 587 | 83 | None | 21% | $439,278 |
| 2015 | 499 | 70 | None | 26% | $506,521 |
| 2014 | 382 | 58 | 0% (0) | 38% | $405,170 |
| 2013 | 288 | 48 | 0% (0) | 48% | $229,570 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Xywav | 62 | $923,523 | $14,896 |
| Wakix | 37 | $513,392 | $13,875 |
| Xyrem | 11 | $211,436 | $19,221 |
| Gabapentin | 14 | $1,221 | $87 |
| Clonazepam | 14 | $480 | $34 |
| Zolpidem | 24 | $407 | $17 |
| Trazodone | 15 | $378 | $25 |
2022: 13 drugs
| Xywav | 64 | $834,175 | $13,034 |
| Wakix | 46 | $549,405 | $11,944 |
| Xyrem | 19 | $299,744 | $15,776 |
| Sunosi | 22 | $17,854 | $812 |
| Trazodone | 41 | $979 | $24 |
| Aripiprazole | 26 | $792 | $30 |
| Dextroamphetamine-Amphet Er | 14 | $546 | $39 |
| Quetiapine | 14 | $462 | $33 |
| Dextroamphetamine-Amphetamine | 12 | $436 | $36 |
| Gabapentin | 16 | $382 | $24 |
| Eszopiclone | 11 | $335 | $30 |
| Clonazepam | 18 | $242 | $13 |
| Zolpidem | 14 | $166 | $12 |
2021: 17 drugs
| Xywav | 90 | $1,032,180 | $11,469 |
| Wakix | 43 | $503,597 | $11,712 |
| Xyrem | 15 | $242,850 | $16,190 |
| Belsomra | 32 | $12,963 | $405 |
| Sunosi | 17 | $12,632 | $743 |
| Armodafinil | 17 | $1,693 | $100 |
| Trazodone | 54 | $1,103 | $20 |
| Modafinil | 17 | $978 | $58 |
| Methylphenidate | 14 | $761 | $54 |
| Dextroamphetamine-Amphet Er | 11 | $563 | $51 |
| Clonazepam | 22 | $543 | $25 |
| Escitalopram | 11 | $535 | $49 |
| Dextroamphetamine-Amphetamine | 12 | $526 | $44 |
| Gabapentin | 38 | $365 | $10 |
| Eszopiclone | 25 | $335 | $13 |
| Mirtazapine | 17 | $260 | $15 |
| Zolpidem | 26 | $133 | $5 |
2020: 18 drugs
| Xyrem | 99 | $1,263,676 | $12,764 |
| Wakix | 36 | $408,683 | $11,352 |
| Sunosi | 32 | $22,410 | $700 |
| Trintellix | 14 | $7,960 | $569 |
| Belsomra | 21 | $7,869 | $375 |
| Bupropion Xl | 25 | $5,221 | $209 |
| Armodafinil | 19 | $3,063 | $161 |
| Doxepin | 18 | $2,365 | $131 |
| Trazodone | 41 | $1,506 | $37 |
| Aripiprazole | 17 | $903 | $53 |
| Methylphenidate | 22 | $887 | $40 |
| Gabapentin | 40 | $497 | $12 |
| Quetiapine | 11 | $391 | $36 |
| Clonazepam | 24 | $293 | $12 |
| Eszopiclone | 22 | $290 | $13 |
| Zolpidem | 43 | $204 | $5 |
| Mirtazapine | 13 | $125 | $10 |
| Citalopram Hbr | 14 | $59 | $4 |
2019: 17 drugs
| Xyrem | 70 | $852,080 | $12,173 |
| Silenor | 36 | $16,329 | $454 |
| Sunosi | 16 | $11,127 | $695 |
| Belsomra | 23 | $8,950 | $389 |
| Aripiprazole | 39 | $5,247 | $135 |
| Modafinil | 25 | $3,958 | $158 |
| Armodafinil | 21 | $1,939 | $92 |
| Bupropion Xl | 32 | $1,851 | $58 |
| Eszopiclone | 40 | $1,328 | $33 |
| Trazodone | 55 | $1,287 | $23 |
| Methylphenidate | 34 | $1,055 | $31 |
| Quetiapine | 20 | $1,034 | $52 |
| Zolpidem | 59 | $700 | $12 |
| Gabapentin | 32 | $537 | $17 |
| Clonazepam | 25 | $270 | $11 |
| Citalopram Hbr | 21 | $103 | $5 |
| Mirtazapine | 11 | $70 | $6 |
2018: 16 drugs
| Xyrem | 58 | $668,276 | $11,522 |
| Silenor | 44 | $18,826 | $428 |
| Modafinil | 58 | $11,143 | $192 |
| Trintellix | 22 | $8,355 | $380 |
| Aripiprazole | 21 | $1,740 | $83 |
| Armodafinil | 21 | $1,627 | $77 |
| Bupropion Xl | 21 | $957 | $46 |
| Trazodone | 36 | $911 | $25 |
| Eszopiclone | 38 | $654 | $17 |
| Methylphenidate | 14 | $529 | $38 |
| Gabapentin | 33 | $485 | $15 |
| Clonazepam | 40 | $352 | $9 |
| Quetiapine | 12 | $311 | $26 |
| Zolpidem | 28 | $192 | $7 |
| Lorazepam | 14 | $104 | $7 |
| Citalopram Hbr | 19 | $83 | $4 |
2017: 16 drugs
| Xyrem | 20 | $165,033 | $8,252 |
| Silenor | 23 | $9,286 | $404 |
| Armodafinil | 16 | $4,450 | $278 |
| Modafinil | 28 | $2,620 | $94 |
| Aripiprazole | 11 | $1,792 | $163 |
| Methylphenidate | 14 | $740 | $53 |
| Trazodone | 27 | $582 | $22 |
| Bupropion Xl | 15 | $442 | $29 |
| Quetiapine | 16 | $411 | $26 |
| Gabapentin | 31 | $355 | $11 |
| Eszopiclone | 23 | $354 | $15 |
| Clonazepam | 37 | $303 | $8 |
| Zolpidem | 26 | $259 | $10 |
| Lorazepam | 15 | $92 | $6 |
| Mirtazapine | 12 | $65 | $5 |
| Citalopram Hbr | 12 | $51 | $4 |
2016: 18 drugs
| Xyrem | 39 | $384,302 | $9,854 |
| Silenor | 20 | $7,600 | $380 |
| Modafinil | 31 | $6,135 | $198 |
| Horizant | 16 | $5,683 | $355 |
| Aripiprazole | 14 | $4,588 | $328 |
| Belsomra | 15 | $4,263 | $284 |
| Methylphenidate | 17 | $1,082 | $64 |
| Zolpidem | 59 | $1,057 | $18 |
| Trazodone | 48 | $787 | $16 |
| Quetiapine | 38 | $646 | $17 |
| Eszopiclone | 27 | $597 | $22 |
| Lorazepam | 27 | $422 | $16 |
| Clonazepam | 48 | $398 | $8 |
| Doxepin | 19 | $326 | $17 |
| Gabapentin | 36 | $286 | $8 |
| Mirtazapine | 21 | $264 | $13 |
| Trihexyphenidyl | 12 | $195 | $16 |
| Citalopram Hbr | 11 | $39 | $4 |
2015: 15 drugs
| Xyrem | 46 | $447,114 | $9,720 |
| Nuvigil | 29 | $18,024 | $622 |
| Modafinil | 30 | $14,244 | $475 |
| Pristiq Er | 22 | $5,420 | $246 |
| Silenor | 15 | $4,279 | $285 |
| Eszopiclone | 36 | $1,675 | $47 |
| Methylphenidate | 11 | $847 | $77 |
| Zolpidem | 36 | $785 | $22 |
| Quetiapine | 47 | $610 | $13 |
| Doxepin | 20 | $431 | $22 |
| Trazodone | 29 | $345 | $12 |
| Trihexyphenidyl | 12 | $191 | $16 |
| Prazosin | 13 | $167 | $13 |
| Clonazepam | 23 | $160 | $7 |
| Lorazepam | 17 | $140 | $8 |
2014: 12 drugs
| Xyrem | 38 | $339,641 | $8,938 |
| Nuvigil | 39 | $22,092 | $566 |
| Modafinil | 20 | $12,781 | $639 |
| Lunesta | 13 | $4,820 | $371 |
| Silenor | 14 | $3,610 | $258 |
| Pristiq Er | 13 | $2,741 | $211 |
| Quetiapine | 25 | $629 | $25 |
| Zolpidem | 41 | $346 | $8 |
| Trazodone | 26 | $222 | $9 |
| Clonazepam | 22 | $183 | $8 |
| Trihexyphenidyl | 12 | $124 | $10 |
| Lorazepam | 13 | $111 | $9 |
2013: 10 drugs
| Xyrem | 29 | $183,614 | $6,332 |
| Nuvigil | 30 | $16,540 | $551 |
| Lunesta | 18 | $5,972 | $332 |
| Silenor | 25 | $4,723 | $189 |
| Pristiq Er | 11 | $1,785 | $162 |
| Trazodone | 36 | $345 | $10 |
| Trihexyphenidyl | 12 | $198 | $16 |
| Clonazepam | 17 | $173 | $10 |
| Zolpidem | 19 | $172 | $9 |
| Mirtazapine | 11 | $120 | $11 |
Money from drug and device companies
$53,675 in 2025
| 2025 | 6 | 47 | $50,346 | $53,675 |
| 2024 | 10 | 195 | $160,824 | $184,533 |
| 2023 | 9 | 296 | $192,196 | $242,442 |
| 2022 | 9 | 247 | $149,998 | $173,911 |
| 2021 | 9 | 305 | $163,584 | $189,628 |
| 2020 | 6 | 216 | $115,130 | $132,934 |
| 2019 | 9 | 211 | $82,800 | $102,903 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Xywav | $23,596 | 28 payments
|
| Noctrix Health | Nidra | $22,975 | 8 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $3,790 | 5 payments
|
| Axsome Therapeutics | Sunosi | $1,688 | 1 payment
|
| Harmony Biosciences | Wakix | $1,597 | 4 payments
|
| Lilly USA | Zepbound | $29 | 1 payment
|
See all 47 published payments
| Noctrix Health | Consulting · 2025-12-01 | Nidra | $1,300 |
| Avadel CNS Pharmaceuticals | Consulting · 2025-11-06 | Lumryz | $545 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-10-14 | Xywav | $5,360 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-10-06 | Xywav | $2,010 |
| Jazz Pharmaceuticals | Travel · 2025-10-04 | Xywav | $217 |
| Jazz Pharmaceuticals | Travel · 2025-10-04 | Xywav | $55 |
| Jazz Pharmaceuticals | Travel · 2025-09-27 | Xywav | $133 |
| Jazz Pharmaceuticals | Meals · 2025-08-19 | Xywav | $21 |
| Noctrix Health | Consulting · 2025-08-01 | Nidra | $650 |
| Jazz Pharmaceuticals | Travel · 2025-07-12 | Xywav | $184 |
| Noctrix Health | Consulting · 2025-07-01 | Nidra | $975 |
| Avadel CNS Pharmaceuticals | Consulting · 2025-06-20 | Lumryz | $1,600 |
| Axsome Therapeutics | Honoraria · 2025-06-17 | Sunosi | $1,688 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-06-11 | Xywav | $2,345 |
| Avadel CNS Pharmaceuticals | Meals · 2025-06-03 | Lumryz | $14 |
| Noctrix Health | Consulting · 2025-06-02 | Nidra | $1,625 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-05-27 | Xywav | $5,360 |
| Jazz Pharmaceuticals | Travel · 2025-05-21 | Xywav | $90 |
| Jazz Pharmaceuticals | Travel · 2025-05-21 | Xywav | $40 |
| Jazz Pharmaceuticals | Travel · 2025-05-21 | Xywav | $34 |
| Jazz Pharmaceuticals | Meals · 2025-05-21 | Xywav | $25 |
| Jazz Pharmaceuticals | Meals · 2025-05-12 | Xywav | $142 |
| Jazz Pharmaceuticals | Travel · 2025-05-10 | Xywav | $211 |
| Jazz Pharmaceuticals | Travel · 2025-05-07 | Xywav | $499 |
| Noctrix Health | Consulting · 2025-05-01 | Nidra | $650 |
| Avadel CNS Pharmaceuticals | Meals · 2025-04-24 | Lumryz | $31 |
| Noctrix Health | Consulting · 2025-04-03 | Nidra | $650 |
| Lilly USA | Meals · 2025-04-02 | Zepbound | $29 |
| Jazz Pharmaceuticals | Travel · 2025-03-12 | Xywav | $148 |
| Jazz Pharmaceuticals | Meals · 2025-03-12 | Xywav | $44 |
| Jazz Pharmaceuticals | Travel · 2025-03-12 | Xywav | $40 |
| Jazz Pharmaceuticals | Travel · 2025-03-12 | Xywav | $33 |
| Jazz Pharmaceuticals | Meals · 2025-03-12 | Xywav | $22 |
| Harmony Biosciences | Meals · 2025-03-05 | Wakix | $44 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-03-05 | Xywav | $5,360 |
| Noctrix Health | Consulting · 2025-02-28 | Nidra | $5,000 |
| Harmony Biosciences | Consulting · 2025-02-27 | Wakix | $501 |
| Jazz Pharmaceuticals | Meals · 2025-02-27 | Xywav | $122 |
| Jazz Pharmaceuticals | Travel · 2025-02-26 | Xywav | $649 |
| Jazz Pharmaceuticals | Travel · 2025-02-22 | Xywav | $50 |
| Harmony Biosciences | Consulting · 2025-02-20 | Wakix | $1,002 |
| Harmony Biosciences | Meals · 2025-02-20 | Wakix | $50 |
| Jazz Pharmaceuticals | Travel · 2025-02-13 | Xywav | $225 |
| Jazz Pharmaceuticals | Meals · 2025-02-12 | Xywav | $20 |
| Noctrix Health | Consulting · 2025-02-10 | Nidra | $12,125 |
| Jazz Pharmaceuticals | Travel · 2025-01-16 | Xywav | $157 |
| Avadel CNS Pharmaceuticals | Consulting · 2025-01-08 | Lumryz | $1,600 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $184,533
| Jazz Pharmaceuticals | Xywav | $87,819 | 77 payments
|
| Harmony Biosciences | Wakix | $38,287 | 47 payments
|
| Axsome Therapeutics | Sunosi | $25,687 | 39 payments
|
| Noctrix Health | Nidra | $20,400 | 7 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $12,034 | 11 payments
|
| Inspire Medical Systems | Inspire | $200 | 9 payments
|
| Fisher & Paykel Healthcare | Fisher & Paykel Healthcare | $33 | 2 payments
|
| Resmed | Airsense | $32 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $23 | 1 payment
|
| Philips North America | (Di4) Pillow Cushions - Over the Head | $18 | 1 payment
|
2023: $242,442
| Harmony Biosciences | Wakix | $91,242 | 104 payments
|
| Jazz Pharmaceuticals | Xywav | $77,059 | 92 payments
|
| Axsome Therapeutics | Sunosi | $61,316 | 78 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $12,576 | 12 payments
|
| Inspire Medical Systems | Inspire | $96 | 2 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $89 | 5 payments
|
| Fisher & Paykel Healthcare | Fisher & Paykel Healthcare | $23 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $18 | 1 payment
|
2022: $173,911
| Harmony Biosciences | Wakix | $90,380 | 112 payments
|
| Jazz Pharmaceuticals | Xywav | $78,762 | 120 payments
|
| Eisai | Dayvigo | $4,636 | 9 payments
|
| Neurocrine Biosciences | Ingrezza | $33 | 1 payment
|
| Vanda Pharmaceuticals | Hetlioz | $31 | 1 payment
|
| Merck Sharp & Dohme | Belsomra | $23 | 1 payment
|
| Resmed | Air 11 | $19 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $14 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $12 | 1 payment
|
2021: $189,628
| Harmony Biosciences | Wakix | $95,414 | 115 payments
|
| Jazz Pharmaceuticals | Sunosi | $93,791 | 173 payments
|
| Teva Pharmaceuticals USA | Austedo | $143 | 4 payments
|
| Merck Sharp & Dohme | Belsomra | $89 | 4 payments
|
| Eisai | Dayvigo | $76 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $55 | 2 payments
|
| Philips Electronics North America | (7999) Src Und | $21 | 1 payment
|
| Vanda Pharmaceuticals | Hetlioz | $20 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $20 | 1 payment
|
2020: $132,934
| Harmony Biosciences | Wakix | $78,669 | 109 payments
|
| Jazz Pharmaceuticals | Sunosi | $53,924 | 88 payments
|
| Vanda Pharmaceuticals | Hetlioz | $220 | 12 payments
|
| Eisai | Dayvigo | $52 | 3 payments
|
| Merck Sharp & Dohme | Belsomra | $45 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $24 | 1 payment
|
2019: $102,903
| Jazz Pharmaceuticals | Xyrem | $102,590 | 186 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $105 | 14 payments
|
| Vanda Pharmaceuticals | Hetlioz | $62 | 3 payments
|
| Arbor Pharmaceuticals | Horizant | $46 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $33 | 2 payments
|
| OptiNose US | Xhance | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $18 | 1 payment
|
| Merck Sharp & Dohme | Belsomra | $16 | 1 payment
|
| Resmed | Airsense | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Prospective, Open-Label, Single-Arm, Multicenter Study To Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 To 75 Years With Idiopathic Hypersomnia Or Narcolepsy · 2025 | This clinician | $211,398 |
| HARMONY BIOSCIENCES LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed By An Open Label Extension · 2022 | Their institution | $68,217 |
| JAZZ PHARMACEUTICALS INC. · A Prospective, Open-Label, Single-Arm, Multicenter Study To Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 To 75 Years With Idiopathic Hypersomnia Or Narcolepsy · 2024 | This clinician | $65,350 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2024 | This clinician | $45,944 |
| Noctrix Health, Inc. · Thrive Study Ct-06 · 2024 | Their institution | $38,800 |
| Harmony Biosciences LLC · An Open-Label Study To Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study Hbs-101-Cl-010 · 2023 | This clinician | $38,393 |
| Harmony Biosciences LLC · A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia · 2023 | This clinician | $27,166 |
| HARMONY BIOSCIENCES LLC · An Open-Label Study To Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study Hbs-101-Cl-010 · 2024 | Their institution | $23,556 |
| HARMONY BIOSCIENCES LLC · A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia · 2022 | This clinician | $16,130 |
| HARMONY BIOSCIENCES LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed By An Open Label Extension · 2023 | Their institution | $16,063 |
| HARMONY BIOSCIENCES LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed By An Open Label Extension · 2021 | Their institution | $12,870 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2025 | This clinician | $11,783 |
| Noctrix Health, Inc. · Thrive · 2025 | Their institution | $10,975 |
| HARMONY BIOSCIENCES LLC · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Pitolisant Followed By An Open-Label Extension in Patients With Prader-Willi Syndrome · 2024 | Their institution | $10,000 |
| HARMONY BIOSCIENCES LLC · A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia · 2023 | Their institution | $7,898 |
| HARMONY BIOSCIENCES LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed By An Open Label Extension · 2021 | This clinician | $6,463 |
| HARMONY BIOSCIENCES LLC · A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia · 2024 | Their institution | $5,449 |
| Harmony Biosciences LLC · Hbs-101-Cl-001 · 2020 | This clinician | $5,000 |
| HARMONY BIOSCIENCES LLC · An Open-Label Study To Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study Hbs-101-Cl-010 · 2023 | Their institution | $3,656 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2024 | Their institution | $2,108 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2023 | Their institution | $1,819 |
| HARMONY BIOSCIENCES LLC · An Open-Label Study To Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study Hbs-101-Cl-010 · 2024 | This clinician | $1,553 |
| JAZZ PHARMACEUTICALS INC. · A Prospective, Open-Label, Single-Arm, Multicenter Study To Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 To 75 Years With Idiopathic Hypersomnia Or Narcolepsy · 2025 | Their institution | $1,319 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2025 | Their institution | $288 |
Professional record
- NPI
- 1154410967
- Licence
- CA A101826, ID MC-0760, IL 036-107869, NV 10976, WA MD60909889California A101826: Current · expires 2027-07-31Illinois 036107869: ActiveWashington MD.MD.60909889: Active
- Trained
- Washington University School of Medicine, 1994
- Group
- Haramandeep Singh MD Inc · Ridgecrest Regional Hospital · Integrated Sleep Care PC · Manakai O Malama Integrative · Maryland Medical Specialists Inc · Alpha Diagnostics Management Inc. · Bay Area Hospital District · Oregon Sleep and Pulmonary LLC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084S0012X (2084S0012X)
- Mailing address
- Po Box 1855, San Ramon, CA, 94583
- NPI first listed
- 2006-10-11
- NPI last updated
- 2025-11-05
- NPI record certified
- 2025-11-05
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.